Ads
related to: drugs, lung cancer- Support Program Sign Up
Register for a Support Program
Including Financial Resources.
- Clinical Study Overview
Review Study Results For An
ALK+ mNSCLC Treatment.
- ALK+ mNSCLC Clinical Info
See More About The Response Rate &
Duration Of Response For A Therapy.
- Patient Assistance Tool
Find Financial Options To Help
Eligible Patients Afford Treatment.
- Support Program Sign Up
Search results
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 3 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
Lack of insurance may prevent Americans from accessing best cancer drugs
United Press International via Yahoo News· 2 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. But the drugs,...
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer
Medical Xpress· 1 day agoA large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung
Strong trial results for Pfizer lung cancer drug | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 5 days agoRoughly half received lorlatinib while the rest received crizotinib, an earlier generation drug....
New pathways for treating never-smoker lung cancer revealed
Medical Xpress· 2 days agoThe primary cause of lung cancer is smoking. However, the incidence of lung cancer among never-smokers has been steadily increasing, especially among women.
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
FierceBiotech· 1 day ago“We want to be part of that wave,” AbbVie Pedro Valencia, Ph.D., AbbVie’s vice president of solid...
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival
Reuters· 5 days agoTrodelvy has accelerated U.S. approval for treating advanced urothelial cancer, but Gilead on...
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer...
Benzinga· 5 days agoAlso Read: Pfizer Agrees To Settle Over 10,000... Cancer Risks Associated With Discontinued...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 3 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Gilead’s Trodelvy extends lung cancer survival by just 1.3 months in trial
WSAU Wausau· 5 days agoBy Deena Beasley (Reuters) - Gilead Sciences' Trodelvy improved survival by 1.3 months more than...
Ads
related to: drugs, lung cancer